Effect of immunostimulatory CpG-oligonucleotides in chronic lymphocytic leukemia B cells

被引:20
作者
Decker, T [1 ]
Peschel, C [1 ]
机构
[1] Tech Univ Munich, Dept Med 3, D-81675 Munich, Germany
关键词
immunostimulation; CpG oligonucleotides; B-CLL cells;
D O I
10.3109/10428190109064586
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Bacterial DNA and phosphothioate oligonucleotides containing a CpG motif (CpG-ODN) can activate cells of the immune system such as monocytes, dendritic cells and B cells. Protective immune responses against pathogens and tumor cells were observed in murine models when mice were treated with CpG-ODN. Recent results have demonstrated strong activation of human immune cells as well. Apart from stimulating cells of the immune system, CpG ODN have many direct effects on B-CLL cells such as upregulation of costimulatory molecules, cell cycle entry and upregulation of potential target antigens for antibody therapy. Therefore, CpG-ODN appear to be attractive compounds to be included into new therapeutic strategies like tumor cell vaccination and adoptive T cell transfer or therapy with monoclonal antibodies. In this review, the effects of CpG-ODN on B-CLL cells are summarized and potential therapeutic applications of CpG-ODN in chronic lymphocytic leukemia are discussed.
引用
收藏
页码:301 / 307
页数:7
相关论文
共 78 条
[1]   Toll signaling pathways in the innate immune response [J].
Anderson, KV .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (01) :13-19
[2]   Dendritic cells and the control of immunity [J].
Banchereau, J ;
Steinman, RM .
NATURE, 1998, 392 (6673) :245-252
[3]   DNA activates human immune cells through a CpG sequence-dependent manner [J].
Bauer, M ;
Heeg, K ;
Wagner, H ;
Lipford, GB .
IMMUNOLOGY, 1999, 97 (04) :699-705
[4]  
BENDIGS S, 1999, EUROPEAN J IMMUNOLOG
[5]   CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: Stimulation of allogeneic versus autologous T cells generates different types of effector cells [J].
Buhmann, R ;
Nolte, A ;
Westhaus, D ;
Emmerich, B ;
Hallek, M .
BLOOD, 1999, 93 (06) :1992-2002
[6]  
Carpentier AF, 1999, CANCER RES, V59, P5429
[7]   CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity [J].
Chu, RS ;
Targoni, OS ;
Krieg, AM ;
Lehmann, PV ;
Harding, CV .
JOURNAL OF EXPERIMENTAL MEDICINE, 1997, 186 (10) :1623-1631
[8]  
Cowdery J, 1996, J IMMUNOL, V156, P4570
[9]   Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity [J].
Davila, E ;
Celis, E .
JOURNAL OF IMMUNOLOGY, 2000, 165 (01) :539-547
[10]   FAILURE OF B-CELLS OF CHRONIC LYMPHOCYTIC-LEUKEMIA IN PRESENTING SOLUBLE AND ALLOANTIGENS [J].
DAZZI, F ;
DANDREA, E ;
BIASI, G ;
DESILVESTRO, G ;
GAIDANO, G ;
SCHENA, M ;
TISON, T ;
VIANELLO, F ;
GIROLAMI, A ;
CALIGARISCAPPIO, F .
CLINICAL IMMUNOLOGY AND IMMUNOPATHOLOGY, 1995, 75 (01) :26-32